The diagnostic and prognostic value of pretreatment serum creatine kinase BB levels in patients with neuroblastoma.
The serum levels of the BB isozyme of creatine kinase (CK-BB) and neuron-specific enolase (NSE) were measured before therapy in 35 patients with neuroblastoma. Sixty percent (21 of 35) of neuroblastoma patients had CK-BB levels higher than 11 ng/ml. The extent of disease was associated with an increased incidence of elevated serum CK-BB levels. The highest pretreatment serum CK-BB titers were found in patients with Stage IV disease. A strong correlation between the pretreatment CK-BB level and the outcome in patients with neuroblastoma was observed. Eleven (79%) of 12 patients who had a serum CK-BB level greater than 15 ng/ml died, and eight of ten (80%) who had a serum level less than 11 ng/ml were alive and tumor free after 2 years. A positive linear correlation between the pretreatment CK-BB and NSE (n = 35, r = 0.695) levels was found.
Ishiguro
Y
Y
Department of Surgery, Branch Hospital of Nagoya University School of Medicine, Japan.
Kato
K
K
Akatsuka
H
H
Ito
T
T
D014408:Biomarkers, Tumor / Q000032:analysis*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003402:Creatine Kinase / Q000032:analysis*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007527:Isoenzymes; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000201:enzymology* / Q000473:pathology / Q000628:therapy; D010751:Phosphopyruvate Hydratase / Q000032:analysis; D011379:Prognosis; D011446:Prospective Studies; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D007527:Isoenzymes; D003402:Creatine Kinase; D010751:Phosphopyruvate Hydratase